[NEW YORK, Feb. 11, 2019, KOREA IT TIMES, GLOBE NEWSWIRE] TikaMobile, a premier cloud-based business intelligence CRM provider for the life sciences industry, today announced that Titan Pharmaceuticals, Inc. has selected Tika’s BI/CRM platform to deliver real-time, actionable intelligence and interactive advanced analytics to its Sales and MSL teams. Titan is focused on the U.S. commercial relaunch of Probuphine® (buprenorphine) implant, its unique six-month maintenance treatment for Opioid Use Disorder (OUD).
With its unique ability to aggregate information and combine the functionality of disparate sales and marketing tools, TikaMobile will operate as Titan’s one-stop solution for its CRM and analytic needs. This will allow Titan to continue to strengthen its product launch process and leverage its Sales team to increase productivity and better drive revenue. Titan’s MSL team will also have insights to better focus on KOLS to build stronger relationships and manage ongoing training initiatives with prescribers.
“We are pleased to be partnering with Titan as they work to change the medical landscape with their unique long-term maintenance treatment for opioid use disorder,” commented Manish Sharma, Chief Executive Officer and founder of TikaMobile. “Our advanced CRM and audience targeting capabilities will provide Titan with the intelligence and insights that their field reps need to increase their productivity, boost revenue generation and enhance the efficiency of their overall business practices.”
“Our field personnel appreciate the user-friendliness of the Tika system and the ability to view complex data in a simple and meaningful way,” said Titan’s EVP and Chief Commercial Officer, Dane Hallberg. “We believe that Tika will provide our teams with a highly efficient way to identify opportunities, support our customers, and more-effectively manage our business in this competitive environment.”
About TikaMobile, Inc.
TikaMobile, Inc. is the premier leader in cloud-based business intelligence and CRM sales enablement software for the global life sciences industry. By combining many disparate sales and marketing tools into a single easy-to-use application, while applying prescriptive, actionable analytics across the commercial organization, Tika is transforming and optimizing sales organizations for pharmaceutical and medical device companies. Tika is committed to innovation, product excellence, and customer success and works with organizations of all sizes. Headquartered in New York City, Tika has offices in the United States, Europe and India. For more information, visit www.tikamobile.com.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a commercial stage company developing proprietary therapeutics with its ProNeura™ long-term, continuous drug delivery technology. The company's lead product is Probuphine® (buprenorphine) implant, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Approved by the U.S. Food and Drug Administration in May 2016, Probuphine is the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura technology also has the potential to be used in developing products for treating other chronic conditions such as Parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com.